Abstract. Clonidine stimulates GH release via release of GH releasing hormone from the hypothalamus. There has been controversy as to its usefulness in the therapy of children with constitutional growth delay.
Clonidine, a selective alpha2-adrenergic agonist, stimulates GH release via release of GH releasing hormone (GHRH) from the hypothalamus.
Some investigators have reported that it was useful in therapy for children with constitutional growth delay (CGD).
In this study, to evaluate the efficacy of clonidine on short stature we administered clonidine to both prepubertal and pubertal children with non-endocrine short stature (NESS) and investigated the changes of linear growth and plasma levels of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3). 
